SW076956|CAS 851717-83-4|Beclin 1/Bcl-2 inhibitor

Cas No.:	851717-83-4
Chemical Name:	N-(4-(5-(furan-2-yl)-1-(4-methylbenzoyl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)methanesulfonamide
Synonyms:	SW-076956,SW 076956
SMILES:	CS(NC1=CC=C(C2CC(C3=CC=CO3)N(C(=O)C3=CC=C(C)C=C3)N=2)C=C1)(=O)=O
Formula:	C₂₂H₂₁N₃O₄S
M.Wt:	423.487
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	SW076956 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity.
References:	References 1. Chiang WC, et al. ACS Chem Biol. 2018 Jun 21. doi: 10.1021/acschembio.8b00421. View Related Products by Target Bcl-2

Cat. No.	Product name	Field of application
DC7950	UMI-77	UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
DC5005	tw-37	TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM, respectively.
DC10965	SW076956	SW076956 is a small molecule that selectively disrupt Beclin 1/Bcl-2 binding as compared to Bax/Bcl-2 and Bim/Bcl-2 binding and induces autophagic flux at concentrations with minimal cytotoxicity.
DC8128	Pyridoclax(MR29072)	Pyridoclax(MR-29072) is a potent Mcl-1 inhibitor with Kd value of 25 nM.
DC10133	Gambogic Acid	Gambogic Acid activates caspases with EC50 of 0.78-1.64 μM and competitively inhibits Bcl-xl, Bcl-2, Bcl-w, Bcl-B, Bfl-1 and Mcl-1 with IC50 of 1.47 μM, 1.21 μM, 2.02 μM, 0.66 μM, 1.06 μM and 0.79 μM, respectively.
DC10447	FX1	FX1 is a novel specific inhibitor of the B cell lymphoma 6 (BCL6).
DC9955	BCL6 inhibitor(CID5721353)	CID5721353 is a B-Cell Lymphoma 6 Inhibitor (BCL6 inhibitor).
DC9695	BH3I-1	BH3I-1 is a cell permeable BH3 mimetic that binds to Bcl-xL. BH3I-1 is an inhibitor of Bcl-xL.
DC1022	ABT-737	ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM, respectively.
DC4127	ABT-263 (Navitoclax)	ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤ 1 nM, respectively.